ncRNA basic information ncRNA ID: MI0000749 ncRNA Database: miRBase ncRNA Name: miR-30e ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: IRS1 ncRNA Pathway: AKT and ERK1/2 pathway Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB01229 (APRD00259, DB05261, DB05927, DB05526, DB05281) Drug Name: Paclitaxel Drug Method: In this study, we found that miR-30e was significantly downregulated in tumor tissues of breast cancer (BC) patients and cell lines, and overexpression of miR-30e inhibited cell proliferation, migration and invasion. To understand the potential mechanism of miR-30e in inhibiting tumor growth, we showed that miR-30e blocked the activation of AKT and ERK1/2 pathways, and the expression of HIF-1alpha and VEGF via directly targeting IRS1. Moreover, miR-30e regulates cell proliferation, migration, invasion and increases chemosensitivity of MDA-MB-231 cells to paclitaxel by inhibiting its target IRS1. MiR-30e also inhibited tumor growth and suppressed expression of IRS1, AKT, ERK1/2 and HIF-1alpha in mouse xenograft tumors. To test the clinical relevance of these results, we used 40 pairs of BC tissues and adjacent normal tissues, analyzed the levels of miR-30e and IRS1 expression in these tissues, and found that miR-30e levels were significantly inversely correlated with IRS1 levels in these BC tissues, suggesting the important implication of our findings in translational application for BC diagnostics and treatment in the future. Drug Response: sensitive

Cancer basic information Cancer: breast cancer Tissue/Cell: cell line ( HEK293T,MCF-7, MDA-MB-231,MCF10A)

Other information Title: MiR-30e inhibits tumor growth and chemoresistance via targeting IRS1 in Breast Cancer. Journal: Biosci Rep Published: 2017 PubMed ID: 29162879